Leland F. Wilson

Mr. Wilson has been a director of VIVUS since the company was formed in April 1991 and chief executive officer since November 1991. Prior to joining VIVUS, Mr. Wilson was vice president of marketing and corporate development of Genelabs Technologies, Inc. from 1989 to 1991. Mr. Wilson was group product director, later promoted to director of marketing, at LifeScan, a Johnson & Johnson company, from 1986 to 1989. From 1973 to 1986, Mr. Wilson served in several research, marketing and sales positions for Syntex Research and Syntex Laboratories, Inc. Mr. Wilson received a B.S. and an M.S. from Pennsylvania State University and was a Lieutenant in the United States Army.

Linda M. Dairiki Shortliffe, M.D.

Dr. Shortliffe has been a director of VIVUS since June 1999. Dr. Shortliffe has been professor of urology at Stanford University School of Medicine since 1993 and chair of the department of urology since 1995. She has also been chief of pediatric urology of Lucile Salter Packard Children's Hospital at Stanford since 1991. She is a fellow of the American College of Surgeons and the American Academy of Pediatrics. Dr. Shortliffe has also served as a member of the special grants chartered review committee for the National Institute of Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health and several other national committees. She has authored numerous publications and her works appear in prominent medical journals and books. Dr. Shortliffe received an A.B. from Radcliffe/Harvard College and an M.D. from Stanford University.

Peter Y. Tam

Mr. Tam has been President since November 2009. Prior to that time, Mr. Tam held various senior management positions at VIVUS, including senior vice president of product and corporate development and vice president of strategic planning and corporate development. Mr. Tam joined VIVUS in 1993 as manager of clinical research, and in 1999 he assumed the responsibilities of director of clinical and corporate development. Prior to VIVUS, Mr. Tam held various research and clinical development positions at Genentech from 1991 through 1993 and XOMA Corporation from 1987 to 1991. Mr. Tam received a B.S. in Chemistry from University of California Berkeley in 1986 and his M.B.A. at Santa Clara University in 2000.

Charles J. Casamento

Mr. Casamento is executive director and principal of the Sage Group, a health care advisory group specializing in business development transactions. Prior to the Sage Group, he was president and CEO of Osteologix, Questcor and Interneuron. Mr. Casamento has held a number of marketing, sales, finance and business development positions with Sandoz, Hoffmann-LaRoche, Johnson & Johnson, American Hospital Supply Corporation and Genzyme. Mr. Casamento is a director and board member at Cortex Pharmaceuticals and SuperGen. A graduate of Fordham University in New York City and Iona College in New Rochelle, New York, Mr. Casamento has a degree in Pharmacy and an MBA.